Head-to-head · Cost-Efficiency Index
Breeze Meds vs Boston Medical Group
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Breeze Meds
People who want to independently verify the clinicians and pharmacy behind their GLP-1 — and who'll pay a mid-market price for that paper trail plus FSA/HSA eligibility.
Visit Breeze MedsBoston Medical Group
Cost-first shoppers who want a clinician-run 12-week programme and can accept a price quoted as a range rather than a rate.
Visit Boston Medical GroupThe verdict
Breeze Meds takes it, leading the Cost-Efficiency Index 86 to 59. The most transparent operator in our partner tier — all-50 compounded GLP-1 with NPI-verifiable named physicians, named pharmacies and LegitScript backing, so you can actually audit who's behind the script. Boston Medical Group still earns a C — Cost-first shoppers who want a clinician-run 12-week programme and can accept a price quoted as a range rather than a rate.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Breeze Meds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Breeze Meds | Boston Medical Group |
|---|---|---|
| Cost-Efficiency Index | 86/100 | 59/100 |
| Semaglutide / mo | $199/mo | $199/mo (starting strength, rising with dose, compounded) |
| Tirzepatide / mo | $399/mo | Not disclosed |
| Semaglutide / yr (modeled) | $2,388 | $2,388 |
| Tirzepatide / yr (modeled) | $4,788 | — |
| Coverage | All 50 states | 7 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Compounded only |
| Rank on the board | #5 | #247 |
Breeze Meds
86/100Where the value is
- Best transparency of this partner batch — NPI-verifiable named physicians (Lion MD group), named dispensing pharmacies, and LegitScript certification
- All 50 states, with injectable semaglutide from $199/mo plus oral semaglutide (~$299) and oral tirzepatide (~$399) for the needle-averse
- FSA/HSA eligible, which trims the effective monthly cost
The tradeoffs
- Mid-to-higher per-month pricing — tirzepatide and the oral routes carry a premium over the cheapest all-50 rivals
- Compounded only — not FDA-approved brand-name medication
Boston Medical Group
59/100Where the value is
- An established medical group with a defined 12-week programme rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
The tradeoffs
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.